![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
Dr. Rajkumar's Guide to the Best Myeloma Abstracts for ASH 2019
Each year over 30,000 doctors, researchers, patient advocates, and patients attend the American Society of Hematology (ASH) conference. To say it is confusing and overwhelming would be an understatement. There are more than 1925 Oral Abstracts and 4039 Poster Abstracts! How does anyone navigate through the maze to make the best use of their time? The Myeloma Crowd has made it a priority to help you with this effort and has asked many of the most skilled and knowledgable myeloma specialists in the world if they would help us in this effort to navigate through the more than 1000 myeloma abstracts to identify those they feel are the most significant.
#1 CC-93269, an asymmetric 2-arm humanized IgG T-cell engager that binds bivalently to BCMA and monovalently to CD3ε is highly active in refractory myeloma
#2 Two abstracts highlighting problem of racial disparity in myeloma. Blacks much less likely to receive Stem Cell Transplant & Lenalidomide. If access is provided, they have better survival.
#3 Great data showing double & triple hit myeloma has Progression Free Survival of only 2 years despite current therapy and shows we need to target and overcome this early in the disease course.
#4 Novel CAR-T targeting both BCMA and CD38. Impressive clinical data already in Phase I. We need these type new approaches for more durable effect from CAR-T.
#5 A great individual patient data meta analysis of auto-auto vs. auto-allo in myeloma. Shows Progression Free Survival and Overall Survival benefit of allo for young patients— but no Overall Survival benefit in high risk patients which is where we have considered using allo.
Each year over 30,000 doctors, researchers, patient advocates, and patients attend the American Society of Hematology (ASH) conference. To say it is confusing and overwhelming would be an understatement. There are more than 1925 Oral Abstracts and 4039 Poster Abstracts! How does anyone navigate through the maze to make the best use of their time? The Myeloma Crowd has made it a priority to help you with this effort and has asked many of the most skilled and knowledgable myeloma specialists in the world if they would help us in this effort to navigate through the more than 1000 myeloma abstracts to identify those they feel are the most significant.
#1 CC-93269, an asymmetric 2-arm humanized IgG T-cell engager that binds bivalently to BCMA and monovalently to CD3ε is highly active in refractory myeloma
#2 Two abstracts highlighting problem of racial disparity in myeloma. Blacks much less likely to receive Stem Cell Transplant & Lenalidomide. If access is provided, they have better survival.
#3 Great data showing double & triple hit myeloma has Progression Free Survival of only 2 years despite current therapy and shows we need to target and overcome this early in the disease course.
#4 Novel CAR-T targeting both BCMA and CD38. Impressive clinical data already in Phase I. We need these type new approaches for more durable effect from CAR-T.
#5 A great individual patient data meta analysis of auto-auto vs. auto-allo in myeloma. Shows Progression Free Survival and Overall Survival benefit of allo for young patients— but no Overall Survival benefit in high risk patients which is where we have considered using allo.
about the author
Gary Petersen
Gary is a myeloma survivor and patient advocate. His work centers around helping patients live longer by helping them to find facilities who are beating the average survival statistics. You can find Gary's site at www.myelomasurvival.com and follow him on Twitter at @grpetersen1
More on Treatment Advances
Trending Articles
Upcoming Events
Get the Latest Multiple Myeloma Updates, Delivered to You.
By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.
Education
News Articles Patient Guides My Journal University Expert Webinars Find a Specialist HealthTree PodcastCommunity
Connect Coach Moves All Events Community Support Groups Black Myeloma Health Resources in SpanishCure Hub
HealthTree Cure Hub Find Side Effects Solutions See Tracked Labs Connect Medical Records Treatment Options Twin Machine Clinical Trial FinderFollow Us
HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.
Copyright © 2025 HealthTree Foundation. All rights reserved.
Tax ID 45-5354811